Definium Therapeutics (DFTX) CFO receives 62,500-share performance-based equity grant

Rhea-AI Filing Summary

Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.

Definium Therapeutics, Inc. reported that Chief Financial Officer Brandi Roberts received a grant of 62,500 Common Shares on August 12, 2026, at a stated price of $0.00 per share as a grant or award. After this award, Roberts directly holds 271,987 Common Shares. The shares represent the second tranche of performance share units originally granted effective June 2, 2025, and remain subject to vesting based on continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones.

Insider Trade Summary

Net Buyer: 62,500 shares

Net Buy 1 txn

Insider Roberts Brandi

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	62,500	$0.00	$0.00

Holdings After Transaction: Common Shares — 271,987 shares (Direct)

Footnotes (1)

1. F1. The common shares represent the second tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

Key Figures

Shares granted: 62,500 Common Shares Price per share: $0.00 per share Total holdings after transaction: 271,987 Common Shares +2 more

5 metrics

Shares granted 62,500 Common Shares Grant, award, or other acquisition on August 12, 2026

Price per share $0.00 per share Stated transaction price for the equity award

Total holdings after transaction 271,987 Common Shares Direct ownership by CFO Brandi Roberts following the award

Original grant effective date June 2, 2025 Performance share unit grant effective date for this second tranche

Vesting employment condition date June 2, 2028 Continued employment required through this date for vesting

Key Terms

performance share units, contingent right, clinical and regulatory milestones, vesting

4 terms

performance share units financial

"The common shares represent the second tranche of performance share units granted"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

contingent right financial

"Each performance share unit represented a contingent right to receive one common share"

clinical and regulatory milestones medical

"based on, and subject to, the achievement of certain clinical and regulatory milestones"

Clinical and regulatory milestones are the key steps a medical product must clear as it is tested on patients and reviewed by government health authorities, such as completing major clinical trials, filing safety and effectiveness data, or receiving marketing approval. Investors watch these checkpoints like milestones on a roadmap because each one sharply changes the odds that a product will reach patients and generate revenue, much like a car passing inspection before it can be sold.

vesting financial

"remain subject to vesting based on the Reporting Person's continued employment"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What did Definium Therapeutics (DFTX) disclose about CFO Brandi Roberts’ equity grant?

Definium Therapeutics disclosed that CFO Brandi Roberts received a grant of 62,500 Common Shares on August 12, 2026. The award is part of a performance share unit grant and is subject to future vesting conditions and milestones.

How many Definium Therapeutics (DFTX) shares does the CFO hold after this Form 4?

Following the reported transaction, CFO Brandi Roberts directly holds 271,987 Common Shares of Definium Therapeutics. This total reflects the addition of 62,500 granted shares that are still subject to vesting and performance conditions.

What are the vesting conditions on the 62,500 Definium Therapeutics (DFTX) shares granted to the CFO?

The 62,500 Common Shares represent the second tranche of performance share units and remain subject to vesting through June 2, 2028. Vesting requires continued employment and achievement of specified clinical and regulatory milestones under the award agreement.

Are the new Definium Therapeutics (DFTX) shares to the CFO tied to performance milestones?

Yes. Each performance share unit represents a contingent right to receive one common share. Delivery of shares depends on achieving certain clinical and regulatory milestones specified in the Performance Share Unit Award Agreement.

Was the Definium Therapeutics (DFTX) CFO’s share grant a market purchase or a compensation award?

The transaction is reported with code A, described as a grant, award, or other acquisition, at a stated price of $0.00 per share. This indicates a compensation-related equity award rather than a market purchase of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 08:30 AM Accepted by SEC EDGAR 08/12/2026 - 08:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Brandi

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/12/2026		A		62,500(1)	A	$0.00	271,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The common shares represent the second tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

	/s/ Mark Sullivan, Attorney-in-Fact for Brandi Roberts	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)